Reasons for failure to proceed to CAR T-cell infusion
| Reasons . | Entire cohort (N = 45), n (%) . | DR-LBCL cohort (n = 22), n (%) . | NDR-LBCL cohort (n = 23), n (%) . |
|---|---|---|---|
| Rapid disease progression | 12 (29) | 7 (33) | 5 (25) |
| Disease progression with CNS disease | 6 (15) | 4 (19) | 2 (10) |
| Poor ECOG PS ≥3 | 7 (17) | 3 (14) | 4 (20) |
| Manufacturing failure | 4 (10) | 2 (10) | 2 (10) |
| Decline due to patient preference | 5 (12) | 1 (5) | 4 (20) |
| Death | 7 (17) (n = 1 sepsis, n = 6 PD) | 4 (19) (n = 1 sepsis, n = 3 PD) | 3 (15) (n = 3 PD) |
| Missing | 4 | 1 | 3 |
| Reasons . | Entire cohort (N = 45), n (%) . | DR-LBCL cohort (n = 22), n (%) . | NDR-LBCL cohort (n = 23), n (%) . |
|---|---|---|---|
| Rapid disease progression | 12 (29) | 7 (33) | 5 (25) |
| Disease progression with CNS disease | 6 (15) | 4 (19) | 2 (10) |
| Poor ECOG PS ≥3 | 7 (17) | 3 (14) | 4 (20) |
| Manufacturing failure | 4 (10) | 2 (10) | 2 (10) |
| Decline due to patient preference | 5 (12) | 1 (5) | 4 (20) |
| Death | 7 (17) (n = 1 sepsis, n = 6 PD) | 4 (19) (n = 1 sepsis, n = 3 PD) | 3 (15) (n = 3 PD) |
| Missing | 4 | 1 | 3 |